Zakile Aliponda Mfumbilwa

Mr. Zakile Aliponda Mfumbilwa

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
MSMartijn J. H. G. Simons
Martijn J. H. G. Simons
VRValesca P. Retel
Valesca P. Retel
BRBram L. T. Ramaekers
Bram L. T. Ramaekers
RBRogier Butter
Rogier Butter
JMJoanne M. Mankor
Joanne M. Mankor
MJManuela Joore
Manuela Joore
Background Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. Objective The objective of this study was to determine the early cost effectiveness of using WGS in diagnostic strategies compared with currently used molecular diagnostics for patients with inoperable stage IIIB,C/IV non-squamous NSCLC from a Dutch healthcare perspective. Methods A decision tree represented the diagnostic pathway, and a cohort state transition model represented disease progression. Three diagnostic strategies were modelled: standard of care (SoC) alone, WGS as a diagnostic test, and SoC followed by WGS. Treatment effectiveness was based on a systematic review. Probabilistic cost-effectiveness analyses were performed, and threshold analyses (using €80,000 per quality-adjusted life-year [QALY]) was used to explore the early cost effectiveness of WGS. Results WGS as a diagnostic test resulted in more QALYs (0.002) and costs (€1534 [incremental net monetary benefit –€1349]), and SoC followed by WGS resulted in fewer QALYs (–0.002) and more costs (€1059 [–€1194]) compared with SoC alone. WGS as a diagnostic test was only cost effective if it was priced at €2000 per patient and identified 2.7% more actionable patients than SoC alone. Treating these additional identified patients with new treatments costing >€4069 per month decreased the probability of cost effectiveness. Conclusions Our analysis suggests that providing WGS as a diagnostic test is cost effective compared with SoC followed by WGS and SoC alone if costs for WGS decrease and additional patients with actionable targets are identified. This cost-effectiveness model can be used to incorporate new findings iteratively and to support ongoing decision making regarding the use of WGS in this rapidly evolving field.

14 July 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
HWHenri B. Wolff
Henri B. Wolff
ESElisabeth M.P. Steeghs
Elisabeth M.P. Steeghs
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
HGHarry Groen
Harry Groen
EAEddy M. Adang
Eddy M. Adang
VCVeerle M.H. Coupe
Veerle M.H. Coupe
PURPOSE: A large number of targeted treatment options for stage IV nonsquamous non–small-cell lung cancer with specific genetic aberrations in tumor DNA is available. It is therefore important to optimize diagnostic testing strategies, such that patients receive adequate personalized treatment that improves survival and quality of life. The aim of this study is to assess the efficacy (including diagnostic costs, turnaround time (TAT), unsuccessful tests, percentages of correct findings, therapeutic costs, and therapeutic effectiveness) of parallel next generation sequencing (NGS)–based versus sequential single-gene–based testing strategies routinely used in patients with metastasized non–small-cell lung cancer in the Netherlands. METHODS: A diagnostic microsimulation model was developed to simulate 100,000 patients with prevalence of genetic aberrations, extracted from real-world data from the Dutch Pathology Registry. These simulated patients were modeled to undergo different testing strategies composed of multiple tests with different test characteristics including single-gene and panel tests, test accuracy, the probability of an unsuccessful test, and TAT. Diagnostic outcomes were linked to a previously developed treatment model, to predict average long-term survival, quality-adjusted life-years (QALYs), costs, and cost-effectiveness of parallel versus sequential testing. RESULTS: NGS-based parallel testing for all actionable genetic aberrations is on average €266 cheaper than single-gene–based sequential testing, and detects additional relevant targetable genetic aberrations in 20.5% of the cases, given a TAT of maximally 2 weeks. Therapeutic costs increased by €8,358, and 0.12 QALYs were gained, leading to an incremental cost-effectiveness ratio of €69,614/QALY for parallel versus sequential testing. CONCLUSION: NGS-based parallel testing is diagnostically superior over single-gene–based sequential testing, as it is cheaper and more effective than sequential testing. Parallel testing remains cost-effective with an incremental cost-effectiveness ratio of 69,614 €/QALY upon inclusion of therapeutic costs and long-term outcomes.

9 January 2024 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
MSMartijn J. H. G. Simons
Martijn J. H. G. Simons
BRBram Ramaekers
Bram Ramaekers
VRValesca P. Retel
Valesca P. Retel
JMJoanne M. Mankor
Joanne M. Mankor
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Objective We aimed to perform an early cost-effectiveness analysis of using a whole-genome sequencing-based tumor mutation burden (WGS-TMB), instead of programmed death-ligand 1 (PD-L1), for immunotherapy treatment selection in patients with non-squamous advanced/metastatic non-small cell lung cancer ineligible for targeted therapy, from a Dutch healthcare perspective. Methods A decision-model simulating individual patients with metastatic non-small cell lung cancer was used to evaluate diagnostic strategies to select first-line immunotherapy only or the immunotherapy plus chemotherapy combination. Treatment was selected using PD-L1 [A, current practice], WGS-TMB [B], and both PD-L1 and WGS-TMB [C]. Strategies D, E, and F take into account a patient’s disease burden, in addition to PD-L1, WGS-TMB, and both PD-L1 and WGS-TMB, respectively. Disease burden was defined as a fast-growing tumor, a high number of metastases, and/or weight loss. A threshold of 10 mutations per mega-base was used to classify patients into TMB-high and TMB-low groups. Outcomes were discounted quality-adjusted life-years (QALYs) and healthcare costs measured from the start of first-line treatment to death. Healthcare costs includes drug acquisition, follow-up costs, and molecular diagnostic tests (i.e., standard diagnostic techniques and/or WGS for strategies involving TMB). Results were reported using the net monetary benefit at a willingness-to-pay threshold of €80,000/QALY. Additional scenario and threshold analyses were performed. Results Strategy B had the lowest QALYs (1.84) and lowest healthcare costs (€120,800). The highest QALYs and healthcare costs were 2.00 and €140,400 in strategy F. In the base-case analysis, strategy A was cost effective with the highest net monetary benefit (€27,300), followed by strategy B (€26,700). Strategy B was cost effective when the cost of WGS testing was decreased by at least 24% or when immunotherapy results in an additional 0.5 year of life gained or more for TMB high compared with TMB low. Strategies C and F, which combined TMB and PD-L1 had the highest net monetary benefit (≥ €76,900) when the cost of WGS testing, immunotherapy, and chemotherapy acquisition were simultaneously reduced by at least 47%, 39%, and 43%, respectively. Furthermore, strategy C resulted in the highest net monetary benefit (≥ €39,900) in a scenario where patients with both PD-L1 low and TMB low were treated with chemotherapy instead of immunotherapy plus chemotherapy. Conclusions The use of WGS-TMB is not cost effective compared to PD-L1 for immunotherapy treatment selection in non-squamous metastatic non-small cell lung cancer in the Netherlands. WGS-TMB could become cost effective provided there is a reduction in the cost of WGS testing or there is an increase in the predictive value of WGS-TMB for immunotherapy effectiveness. Alternatively, a combination strategy of PD-L1 testing with WGS-TMB would be cost effective if used to support the choice to withhold immunotherapy in patients with a low expected benefit of immunotherapy.

9 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
JWJanneke A. Wilschut
Janneke A. Wilschut
MSMartijn J. H. G. Simons
Martijn J. H. G. Simons
BRBram Ramaekers
Bram Ramaekers
MJManuela Joore
Manuela Joore
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies. However, these improvements come at considerable costs, highlighting the need to assess their cost-effectiveness in order to optimize lung cancer care. Traditionally, cost-effectiveness models for the evaluation of new lung cancer treatments were based on the findings of the randomized control trials (RCTs). However, the strict RCT inclusion criteria make RCT patients not representative of patients in the real-world. Patients in RCTs have a better prognosis than patients in a real-world setting. Therefore, in this study, we developed and validated a diagnosis-treatment decision model for patients with advanced (inoperable) non-squamous NSCLC based on real-world data in the Netherlands. The model is a patient-level microsimulation model implemented as discrete event simulation with five health events. Patients are simulated from diagnosis to death, including at most three treatment lines. The base-model (non-personalized strategy) was populated using real-world data of patients treated with platinum-based chemotherapy between 2008 and 2014 in one of six Dutch teaching hospitals. To simulate personalized care, molecular tumor characteristics were incorporated in the model based on the literature. The impact of novel targeted treatments and immunotherapies was included based on published RCTs. To validate the model, we compared survival under a personalized treatment strategy with observed real-world survival. This model can be used for health-care evaluation of personalized treatment for patients with advanced (inoperable) NSCLC in the Netherlands.

1 January 2025 in Transboundary and Emerging Diseases
Verified
Journal Article
Open access
CMCLARA YONA MWASOTA
CLARA YONA MWASOTA
MMMariam R. Makange
Mariam R. Makange
EMEva Moshiro
Eva Moshiro
Jean HakizimanaJean Hakizimana
Jean Hakizimana
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
Gerald MisinzoGerald Misinzo
Gerald Misinzo
African swine fever (ASF) is a hemorrhagic disease of domestic pigs and wild boars. The ASF virus (ASFV), a sole member of the family Asfarviridae and genus Asfivirus , causes this devastating disease. In sub‐Saharan Africa, ASFV is maintained through three interlinked cycles: the domestic cycle, the pig‐tick cycle, and the sylvatic cycle, which collectively sustain its endemic presence in the region. Interaction between wild and domestic pigs at livestock–wildlife interfaces, particularly in protected areas, poses a significant threat to smallholder farmers. This study aimed to investigate the socioeconomic impact and identify potential risk factors associated with ASF in Serengeti National Park’s (SNP’s) wildlife management area (WMA) in Tanzania. A cross‐sectional study involving 110 domestic pig‐keeping households in the five villages of SNP’s WMA was carried out. A semistructured questionnaire was used to collect data on risk factors and socioeconomic impact associated with ASF from consenting smallholder farmers. Additionally, the observational approach was used to assess pig production’s facilities, behaviors and practices involved in domestic pig production and management. Tissue samples including spleen, lymph nodes, and kidney were also collected from dead domestic pigs belonging to two villages, Nattambiso and Robanda, to confirm the existence of the virus in the study area by using polymerase chain reaction (PCR). Descriptive statistics, univariable, and multivariable logistic analyses were performed to determine risk factors associated with ASF occurrence between October 2021 and April 2022 in the study area. A total of 12 ASF outbreaks affecting 1198 cases that led to 969 domestic pig deaths were reported. The ASFV was confirmed to be positive in all domestic pigs from which tissue samples were collected in the included villages. The case fatality rates (CFRs) from the reported previous ASF incidence varied from 77.5% to 85.2% with an overall CFR of 80.8%. A sum of 163,300,000 Tanzanian Shillings (approximately equivalent to 70,085 USD) loss was recorded in the studied WMA. The major risk factors that correlated with ASF occurrence were encountered ASF previously (odds ratio [OR] = 13.58, 95% confidence interval [CI] = 2.79–87.28), selling pig products with ASF before (OR = 9.43, CI = 1.76–70.02), whilst taking no risk action to prevent loss (OR = 0.14, CI = 0.03–0.63) and swill treatment (OR = 0.10, CI = 0.01–0.54) negatively correlated with ASF. Improving awareness on farm‐level biosecurity, husbandry, and management practices is vital to preventing ASF outbreaks and wildlife spillover, safeguarding livestock health, and promoting economic stability in wildlife–livestock–human interfaces.

9 July 2025 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
ZMZakile Aliponda Mfumbilwa
Zakile Aliponda Mfumbilwa
JWJanneke A. Wilschut
Janneke A. Wilschut
HGHarry Groen
Harry Groen
VRValesca P. Retel
Valesca P. Retel
BRBram Ramaekers
Bram Ramaekers
VCVeerle M.H. Coupe
Veerle M.H. Coupe
Background Pembrolizumab shows effectiveness in treating metastatic non-small cell lung cancer (metNSCLC), with a subgroup of patients experiencing long-term survival (LTS) benefits. The existence of a LTS subgroup may influence the cost-effectiveness of pembrolizumab monotherapy compared with platinum-based chemotherapy. This study aims to assess the potential implications of such a subgroup on the cost-effectiveness for patients with non-squamous metNSCLC and PD-L1 ≥ 50% who are ineligible for targeted therapies. Methods This study used a decision analytic model based on Dutch real-world data (2008–2014). Two strategies were simulated: (1) a chemotherapy strategy: patients receive chemotherapy in the first-, second-, and third-line; and (2) a pembrolizumab strategy: patients receive first-line pembrolizumab followed by chemotherapy for those progressing to second- and third-lines. The pembrolizumab strategy is evaluated with and without the assumption that there is a LTS subgroup. The LTS subgroup is assumed to be free from metNSCLC-related progression after treatment. Costs (2022 €), including drug costs, other direct medical costs, family costs, and healthcare costs in life years gained, are considered from first-line treatment to death. Effects are measured in quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) is assessed using an €80,000/QALY threshold. Threshold analyses are performed on the size and mortality rate of the LTS subgroup and on the price of pembrolizumab. Results QALYs per patient were 0.65 for chemotherapy, 1.24 for pembrolizumab without LTS, and 3.52 for pembrolizumab with LTS. Average costs per patient were €58,800 for chemotherapy, €154,600 for pembrolizumab without LTS, and €178,600 for pembrolizumab with LTS. Pembrolizumab without LTS was not cost-effective compared with chemotherapy (ICER €167,600/QALY), but pembrolizumab with LTS (30% of simulated population) was cost effective (ICER of €43,100/QALY). Threshold analyses showed that a LTS subgroup size of at least 10% or halving the price of pembrolizumab was needed for pembrolizumab to be cost-effective. Conclusions Pembrolizumab is a cost-effective first-line treatment for patients with metNSCLC and PD-L1 ≥ 50% in the Netherlands when at least 10% of patients are long-term survivors. Without long-term survivors, this treatment is not cost-effective. Therefore, it is crucial to consider long-term survivors in assessing the cost-effectiveness of immunotherapy in metNSCLC.